A phase I/II trial of ganetespib in combination with paclitaxel and trastuzumab in HER2-positive breast cancer and ganetespib in combination with paclitaxel in triple negative breast cancer

Trial Profile

A phase I/II trial of ganetespib in combination with paclitaxel and trastuzumab in HER2-positive breast cancer and ganetespib in combination with paclitaxel in triple negative breast cancer

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Feb 2012

At a glance

  • Drugs Ganetespib (Primary) ; Paclitaxel; Trastuzumab
  • Indications Advanced breast cancer; Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Feb 2012 Preliminary results are expected by the end of 2012, according to a Synta Pharmaceuticals media release.
    • 22 Feb 2012 Planned initiation date changed from 1 Dec 2012 to 1 Mar 2012.
    • 22 Feb 2012 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top